EXAGEN INC. Revenue
EXAGEN INC. (XGN) reported Revenue of $19.94 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Income Statement
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2026-08-04
- EXAGEN INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-06-30 was $19.94M, a 15.92% increase year-over-year.
- EXAGEN INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-03-31 was $17.31M, a 11.67% increase year-over-year.
- EXAGEN INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-12-31 was $16.63M, a 21.79% increase year-over-year.
- EXAGEN INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-09-30 was $17.24M, a 37.87% increase year-over-year.
- EXAGEN INC. revenue from contract with customer, excluding assessed tax for fiscal 2025 was $66.58M, a 19.65% increase from fiscal 2024.
- EXAGEN INC. revenue from contract with customer, excluding assessed tax for fiscal 2024 was $55.64M, a 5.89% increase from fiscal 2023.
- EXAGEN INC. revenue from contract with customer, excluding assessed tax for fiscal 2023 was $52.55M, a 15.33% increase from fiscal 2022.
- EXAGEN INC. revenue from contract with customer, excluding assessed tax for fiscal 2022 was $45.56M, a 5.66% decline from fiscal 2021.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 3 month as first filed | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month as first filed | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | $19.94M 10-Q · filed 2026-08-04 | $37.25M 10-Q · filed 2026-08-04 | $53.88M derived: sum of 3 quarters · filed 2026-08-04 | $71.12M derived: sum of 4 quarters · filed 2026-08-04 | ||
| 2026-03-31 | $17.31M 10-Q · filed 2026-05-11 | $33.94M derived: sum of 2 quarters · filed 2026-05-11 | $51.18M derived: sum of 3 quarters · filed 2026-05-11 | $68.38M derived: sum of 4 quarters · filed 2026-08-04 | ||
| 2025-12-31 | $16.63M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $33.88M derived: sum of 2 quarters · filed 2026-03-10 | $51.08M derived: sum of 3 quarters · filed 2026-08-04 | $66.58M 10-K · filed 2026-03-10 | ||
| 2025-09-30 | $17.24M 10-Q · filed 2025-11-04 | $34.45M derived: sum of 2 quarters · filed 2026-08-04 | $49.94M 10-Q · filed 2025-11-04 | $63.60M derived: sum of 4 quarters · filed 2026-08-04 | ||
| 2025-06-30 | $17.20M 10-Q · filed 2026-08-04 | $32.70M 10-Q · filed 2026-08-04 | $46.35M derived: sum of 3 quarters · filed 2026-08-04 | $58.86M derived: sum of 4 quarters · filed 2026-08-04 | ||
| 2025-03-31 | $15.50M 10-Q · filed 2026-05-11 | $29.15M derived: sum of 2 quarters · filed 2026-05-11 | $41.66M derived: sum of 3 quarters · filed 2026-05-11 | $56.72M derived: sum of 4 quarters · filed 2026-05-11 | ||
| 2024-12-31 | $13.65M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $26.16M derived: sum of 2 quarters · filed 2026-03-10 | $41.23M derived: sum of 3 quarters · filed 2026-03-10 | $55.64M 10-K · filed 2026-03-10 | ||
| 2024-09-30 | $12.51M 10-Q · filed 2025-11-04 | $27.57M derived: sum of 2 quarters · filed 2025-11-04 | $41.99M 10-Q · filed 2025-11-04 | $55.75M derived: sum of 4 quarters · filed 2025-11-04 | ||
| 2024-06-30 | $15.06M 10-Q · filed 2025-07-29 | $29.48M 10-Q · filed 2025-07-29 | $43.24M derived: sum of 3 quarters · filed 2025-07-29 | $56.66M derived: sum of 4 quarters · filed 2025-07-29 | ||
| 2024-03-31 | $14.41M 10-Q · filed 2025-05-05 | $28.18M derived: sum of 2 quarters · filed 2025-05-05 | $41.60M derived: sum of 3 quarters · filed 2025-05-05 | $55.73M derived: sum of 4 quarters · filed 2025-05-05 | ||
| 2023-12-31 | $13.77M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | $27.18M derived: sum of 2 quarters · filed 2025-03-11 | $41.32M derived: sum of 3 quarters · filed 2025-03-11 | $52.55M 10-K · filed 2025-03-11 | ||
| 2023-09-30 | $13.42M 10-Q · filed 2024-11-12 | $27.55M derived: sum of 2 quarters · filed 2024-11-12 | $38.78M 10-Q · filed 2024-11-12 | $51.62M derived: sum of 4 quarters · filed 2024-11-12 | ||
| 2023-06-30 | $14.14M 10-Q · filed 2024-08-05 | $25.37M 10-Q · filed 2024-08-05 | $38.20M derived: sum of 3 quarters · filed 2024-08-05 | $52.93M derived: sum of 4 quarters · filed 2024-08-05 | ||
| 2023-03-31 | $11.23M 10-Q · filed 2024-05-13 | $24.07M derived: sum of 2 quarters · filed 2024-05-13 | $38.79M derived: sum of 3 quarters · filed 2024-05-13 | $46.40M derived: sum of 4 quarters · filed 2024-05-13 | ||
| 2022-12-31 | $12.84M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-18 | $27.56M derived: sum of 2 quarters · filed 2024-03-18 | $35.17M derived: sum of 3 quarters · filed 2024-03-18 | $45.56M 10-K · filed 2024-03-18 | ||
| 2022-09-30 | $14.73M 10-Q · filed 2023-11-13 | $22.33M derived: sum of 2 quarters · filed 2023-11-13 | $32.73M 10-Q · filed 2023-11-13 | $45.41M derived: sum of 4 quarters · filed 2023-11-13 | ||
| 2022-06-30 | $7.61M 10-Q · filed 2023-08-07 | $8.96M 10-Q · filed 2022-08-04 | $18.00M 10-Q · filed 2023-08-07 | $19.36M 10-Q · filed 2022-08-04 | $30.69M derived: sum of 3 quarters · filed 2023-08-07 | $42.94M derived: sum of 4 quarters · filed 2023-08-07 |
| 2022-03-31 | $10.39M 10-Q · filed 2023-05-15 | $23.08M derived: sum of 2 quarters · filed 2023-05-15 | $35.33M derived: sum of 3 quarters · filed 2023-05-15 | $48.11M derived: sum of 4 quarters · filed 2023-05-15 | ||
| 2021-12-31 | $12.69M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-20 | $24.94M derived: sum of 2 quarters · filed 2023-03-20 | $37.71M derived: sum of 3 quarters · filed 2023-03-20 | $48.30M 10-K · filed 2023-03-20 | ||
| 2021-09-30 | $12.25M 10-Q · filed 2022-11-21 | $25.02M derived: sum of 2 quarters · filed 2022-11-21 | $35.61M 10-Q · filed 2022-11-21 | $48.28M derived: sum of 4 quarters · filed 2022-11-21 | ||
| 2021-06-30 | $12.77M 10-Q/A · filed 2022-11-21 | $23.36M 10-Q/A · filed 2022-11-21 | $36.03M derived: sum of 3 quarters · filed 2022-11-21 | $46.80M derived: sum of 4 quarters · filed 2022-11-21 | ||
| 2021-03-31 | $10.59M 10-Q · filed 2022-05-11 | $23.25M derived: sum of 2 quarters · filed 2022-05-11 | $34.03M derived: sum of 3 quarters · filed 2022-05-11 | $42.98M derived: sum of 4 quarters · filed 2022-05-11 | ||
| 2020-12-31 | $12.67M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-22 | $23.44M derived: sum of 2 quarters · filed 2022-03-22 | $32.39M derived: sum of 3 quarters · filed 2022-03-22 | $41.98M 10-K · filed 2022-03-22 | ||
| 2020-09-30 | $10.78M 10-Q · filed 2021-11-10 | $19.72M derived: sum of 2 quarters · filed 2021-11-10 | $29.31M 10-Q · filed 2021-11-10 | $39.52M derived: sum of 4 quarters · filed 2021-11-10 | ||
| 2020-06-30 | $8.95M 10-Q · filed 2021-08-09 | $18.53M 10-Q · filed 2021-08-09 | $28.75M derived: sum of 3 quarters · filed 2021-08-09 | $39.19M derived: sum of 4 quarters · filed 2021-08-09 | ||
| 2020-03-31 | $9.58M 10-Q · filed 2021-05-11 | $19.80M derived: sum of 2 quarters · filed 2021-05-11 | $30.24M derived: sum of 3 quarters · filed 2021-05-11 | $40.71M derived: sum of 4 quarters · filed 2021-05-11 | ||
| 2019-12-31 | $10.21M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-16 | $20.65M derived: sum of 2 quarters · filed 2021-03-16 | $31.13M derived: sum of 3 quarters · filed 2021-03-16 | $40.39M 10-K · filed 2021-03-16 | ||
| 2019-09-30 | $10.44M 10-Q · filed 2020-11-10 | $20.91M derived: sum of 2 quarters · filed 2020-11-10 | $30.17M 10-Q · filed 2020-11-10 | $39.81M derived: sum of 4 quarters · filed 2020-11-10 | ||
| 2019-06-30 | $10.47M 10-Q · filed 2020-07-28 | $19.73M 10-Q · filed 2020-07-28 | $29.38M derived: sum of 3 quarters · filed 2020-07-28 | $37.60M derived: sum of 4 quarters · filed 2020-07-28 | ||
| 2019-03-31 | $9.26M 10-Q · filed 2020-05-11 | $18.90M derived: sum of 2 quarters · filed 2020-05-11 | $27.12M derived: sum of 3 quarters · filed 2020-05-11 | |||
| 2018-12-31 | $9.64M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-25 | $17.86M derived: sum of 2 quarters · filed 2020-03-25 | $32.44M 10-K · filed 2020-03-25 | |||
| 2018-09-30 | $8.22M 10-Q · filed 2019-11-12 | $22.80M 10-Q · filed 2019-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| BIODESIX INC (BDSX) | United States | $0.312B | |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| BioNexus Gene Lab Corp (BGLC) | $0.004B | ||
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |